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ABSTRACT 
Objective: Econazole nitrate (ECZ) is one of the triazole antifungal drugs with poor aqueous solubility and dissolution rate; there is a need for 
enhancement of solubility. Therefore; inclusion complexation with β cyclodextrin (βCD) was performed. 
Methods: In this study kneading method and co-evaporation method of preparation of inclusion complex between βCD and ECZ using two molar 
ratios of βCD. The solubility of these complexes in isotonic saline solution and distilled water was studied. Complexes prepared by kneading method 
were used for the preparation of different ophthalmic gel formulas using carbomer (CB) and sodium carboxymethylcellulose (sod CMC) as a gelling 
agent. The release profile and the rheological behaviour of the gel were studied.  
Results: The solubility of ECZ was enhanced by complexation with β CD, and both complexation methods showed Ap type solubility curve, but the 
solubility of ECZ was significantly enhanced by complexation using kneading method over co-evaporation. EZC-βCD complex prepared by kneading 
method with 0.88 *10-3 MβCD molar ratio and formulated in a gel using CB 0.75% w/w and sod CMC 0.25% w/w may be considered as a good 
candidate for ECZ ophthalmic gel dosage form, which showed Super case II transport release profile, and pseudo-plastic shear thinning behavior. 
Conclusion: Kneading method was found to be the best method for inclusion of ECZ into βCD, which significantly enhanced ECZ solubility; enabling 
to be formulated into an ophthalmic gel using CB as a polymer, for further development. 
Keywords: Econazole nitrate, β cyclodextrin, Kneading method, Ophthalmic gel 




Ocular fungal infections, or ophthalmic mycoses, are being 
increasingly recognized as an important cause of morbidity and 
blindness; certain types of ophthalmic mycoses may even be life-
threatening. Keratitis (corneal infection) is the most frequent 
presentation, but the orbit, lids, lacrimal apparatus, conjunctiva, 
sclera, and intraocular structures may also be involved Candida are 
one of the main causative agents of fungal keratitis, especially in 
diabetic and immunocompromised patients, or on long-term use of 
topical steroids [1]. Candida which acidifies the host environment, 
leading to the production of potent virulence factors, to enhance 
adherence to the host and compromising the host defence mechanism 
[2]. Econazole (ECZ), an imidazole with a similar molecular structure 
to miconazole is used primarily in the treatment of superficial 
mycoses, with some studies involving systemic use. It has been little 
studied in the treatment of eye infections, but there are some reports 
of topical administration to treat fungal keratitis [3]. Mahashabde et al. 
suggested the use of ECZ ointment as a prophylactic treatment after 
ocular trauma with the risk of fungal infection [4]. ECZ was formulated 
as ophthalmic ointments 1%w/w in an ointment base and found to be 
stable over 2 y in dark containers [5]. 
ECZ has low aqueous solubility because of its hydrophobic structure; 
this can have a negative impact on antifungal efficacy, pharmaco-
kinetic variability (90% of topically applied cream remain on the 
skin surface) [6] and development of drug resistance [7]. The 
solubility of poorly water-soluble ECZ can be altered in many ways; 
such as the addition of co-solvents, [8] addition of surfactants, [9, 
10] modification of drug crystal forms by solid dispersion and 
complexation with cyclodextrin, [11] or inclusion in a mesoporous 
silicate complex [12]. 
Among these possibilities, the cyclodextrin approach is of particular 
interest. Cyclodextrins are cyclic (α-1,4)-linked oligosaccharides of α-
d-glucopyranose, (oligomer of glucose) containing a relatively 
hydrophobic central cavity and hydrophilic outer surface. Owing to the 
lack of free rotation about the bonds connecting the glucopyranose 
units, the cyclodextrin are not perfectly cylindrical molecules but 
toroidal or cone-shaped. Based on this architecture, the primary 
hydroxyl groups are located on the narrow side of the cone shape, 
while the secondary hydroxyl groups are located on the wider edge. 
The hydrophobic cavity of cyclodextrin is capable of trapping a variety 
of molecules within to produce inclusion complexes, β cyclodextrin β 
CD (seven α-d-glucopyranose oligomers) is the most widely used and 
available cyclodextrin, and its cavity size is suitable for wide range of 
guest molecules, although it has the least solubility; therefore many 
soluble derivatives of β cyclodextrin were produced [13, 14]. 
Many advantages of drugs complex with cyclodextrin have been 
reported in the scientific literature, especially the more soluble 
derivatives, which includes increased solubility, [15, 16] enhanced 
bioavailability [17, 18], etc. the more soluble cyclodextrin derivatives 
were used in numerous topical ophthalmic solutions [19]. 
Ophthalmic solutions are inefficient due to low bioavailability of 
medicines, caused by rapid turnover of tears, and poor patient 
compliance due to repetitive applications. Viscous liquid and semisolid 
preparations; give alternative therapeutic options, by increasing the 
residence time of drugs in an ocular cul-de-sac and prolonging the drug 
to eye contact duration and consequently enhancing the bioavailability 
of ophthalmic medications and reducing the patient non-compliance 
problem. Gel delivery systems have several advantages such as the ease 
of administration, none greasy, acceptable consistency, patient 
compliance, the high residence time in eye and better drug release, using 
various polymers like sodium carboxymethyl-cellulose SCMC, 
hydroxypropylmethylcellulose HPMC etc [20-22]. 
The aim of this study was to investigate the use of a complexing 
agent β-cyclodextrin in two ratios and using two methods of 
preparation to enhance the solubility of ECZ Then these complexes 
were formulated as ophthalmic gels. The developed gels were 
evaluated for their in vitro release of ECZ and rheological behaviour.  
MATERIALS AND METHODS 
Materials 
Econazole nitrate ECZ was supplied by Al-Safa factory (mol wt. 
444.7), β-cyclodextrin (HiMedia lab. Pvt. Ltd, Mumbai, India) (Mol. 
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Wt. 1135), carbomer carbopol 940 (CB) (HiMediaLab. Pvt Ltd, 
Mumbai, India), sodium carboxymethylcellulose (Sod CMC) (BDH 
Chemicals, Ltd. Poole, England), boric acid (CARLO ERBA Reagents 
Strada Rivoltana Italy), EDTA (Schalau Chemie S. A. Spain), 
triethanolamine (TEA) (Hopkins and Williams Ltd. England). 
Methods 
Preparation of inclusion complexes 
ECZ with increasing concentration of β CD were mixed together 
using two different methods of complexation.  
A-kneading method 
A physical mixture of ECZ and βCD was prepared by mixing ECZ with 
βCD and levigated in a mortar with a small volume of water-ethanol 
(50/50 v/v) to form a slurry, the sample was kept overnight in a 
desiccator to remove trace of solvent. [23]. 
B-Co-evaporation method 
ECZ was dissolved in sufficient quantity of ethanol and while βCD 
was dissolved in sufficient quantity of distilled water at 25 °C; and 
after the powders were completely dissolved in each solvent; the 
two solutions were combined together. The solvents were then 
removed using a drying oven (Memmert, GmbH Germany) at 40 °C 
to get the dry powder complex [24]. 
Solubility and phase solubility diagram 
The solubility of ECZ alone and ECZ-βCD complexes prepared by A 
and B methods were determined in both isotonic saline solution and 
in distilled water by adding an excess of powder into flasks 
containing the above media. The flasks were sealed and shaken in a 
water bath (Memmert, Germany) at 25 °C for 48 h [25]. Samples 
were withdrawn, filtered and analyzed using Biotech 9200 UV 
Visible Spectrophotometer for the amount of ECZ solubilized at its 
λmax 271 nm [26]. 
The apparent stability constant of the ECZ-βCD complexes; was 
calculated from the slope of the plot ECZ solubility vs. βCD 
concentration, usingEq.1 and Eq.2 from the drug solubility in 
absence of cyclodextrin, intrinsic solubility [S0] (the intercept) and 
[St] and [Lt] which are the concentrations of ECZ and βCD in 
solution, respectively [27] and the complexation efficacy CE was 


























Preparation of the ophthalmic gel 
According to the results of the solubility study, complexes obtained 
by kneading method were used to prepare different ophthalmic gel 
formulas, as shown in table 1. 
 
Table 1: The composition of various econazole nitrate ophthalmic gels (%w/w) 
ECZ: βCD SCMC CB EDTA Boric acid Water q. s. 
1 0.25 0.5 0.1 1.5 100 
1 0.25 0.75 0.1 1.5 100  
1 0.25 1 0.1 1.5 100  
ECZ: βCD is the econazole: cyclodextrin complex, SCMC is sodium carboxymethylcellulose, CB is carbomer 940 
 
CB, SCMC and a weighed amount of complex equivalent to 1% of the 
drug with βCD molar ratios of either (0.88× 10 M)or (1.76 × 10 M) 
were dispersed in distilled water with continuous mixing using mortar 
and pestle until a homogenous mixture is obtained. Aqueous solution of 
EDTA and boric acid was added to the previous mixture with continuous 
mixing and the final weight of the gel was adjusted to 100 grams using 
distilled water. The final pH of the prepared gels was brought to eye pH 
by using TEA. [29] The prepared ECZ gels were inspected visually for 
their color. The pH of the gel was measured using pH meter. (Hanna 
instruments pH 211 Microprocessor, Italy). 
Drug content 
The drug content was determined by diluting 1 g of the formulation 
to 100 ml with an isotonic saline solution [30]. Aliquot of 1 ml was 
withdrawn and further diluted to 10 ml with the same solution ECZ 
concentration was then determined spectrophotometrically [31] 
In vitro release study of ECZ ophthalmic gels  
The in vitro release study of ECZ from the prepared formulation was 
studied by using a modified USP dissolution apparatus. (Copley 
Scientific TDL England). 
1 gram of ECZ ophthalmic gel was placed in folded filter paper inside 
the dissolution basket. The basket was attached to the metallic drive 
shaft immersed in the dissolution media containing 250 ml of 
isotonic saline solution at 37 °C±1so that the filter paper is slightly 
suspended in dissolution media. The shaft was rotated at 50 rpm 
Aliquot each of 5 ml volume was withdrawn at regular time intervals 
and replaced by an equal volume of dissolution media [32]. The 
absorbance of each sample was measured at 271 nm and converted 
to concentration using calibration curve of ECZ in isotonic saline 
solution. Each test was done in triplicates. 
Kinetics of drug release  
Drug release data were fitted on zero (Eq. 4), Korsmeyer Peppas 
(Eq.5) and to Peppas Sahlin equation (Eq.5) to describe drug release 
from the polymeric system using a Microsoft Excel plug-in program 
DDSolver [33]. 









Peppas Sahlin  = 1
 + 2
2  (6) 
Where F denotes the fraction of drug release at time t, K denotes the 
proportionality constant of release accordingly and (n) and (m) are 
the release index. When n or m = 0.5 the drug release from a thin 
film polymer will correspond to Fickian release, and it may be less 
for cylinders (0.45) and spheres (0.43). If n or m =1 this indicate 
zero-order kinetics if 0.5<n or m<1 it indicates anomalous release 
kinetics. Lastly when n or m>1 Super case II transport is apparent 
for thin films, (>0.89) for cylinders, and (>0.85) for spheres [34]. 
While Peppas Sahlin describes two steps of release, the initial 
release from fixed shape platform, then a secondary release, this 
equation is similar to Korsmeyer Peppas, with two steps of release. 
The most appropriate equation with the goodness of fit R2 will be 
selected as the release model [33]. 
Rheology studies 
The viscosity of the prepared gels was measured at room 
temperature using (Myr VR 3000, Spain) cup and bob rotational 
viscosity (a viscometer comparable to a Brookfield viscometer). The 
samples were sheared with spindle R7 rotated at speeds starting 
from 20 to 200 rpm in ascending order; each sample was rotated for 
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2 min. before each reading, [35] then the sample was allowed to 
rotate in descending order [36, 37]. 
Statistical analysis 
Solubility and release data were subjected to one–way (t-test) using 
Microsoft Excel 2010. The data were considered significant at (p<0.05).  
RESULTS AND DISCUSSION  
Solubility study and phase solubility diagram 
The solubility of ECZ alone and ECZ-β CD complexes using two 
methods (kneading and co-evaporation) in both isotonic saline 
solution and distilled water were studied as seen in fig. 1. 
 
 
Fig. 1: The solubility of ECZ and ECZ-βCD complexes in isotonic saline solution and DW (mean±SD, n=3) 
 
The solubility of ECZ was 0.252 mg/ml and 0.197 mg/ml in isotonic 
saline solution and distilled water respectively. ECZ exhibited about 
1.3 times solubility in isotonic saline solution more than water, 
which may be attributed to the acidic nature of isotonic saline 
solution (pH 5.5) [38]. ECZ nitrate is very basic with a pKa of 6.67, 
therefore, it is more soluble in the more acidic solution. However, it 
may affect the complexation of the ionized ECZ with the neutral CD 
[39] and decrease the size of the stability constant [40]. 
Complexation by kneading method significantly enhanced the 
solubility of ECZ in both media (p<0.05) comparing with the 
solubility of ECZ alone. The driving force for complexation is the 
release of the enthalpy rich water molecules from the inside of the 
cone, and formation of non-polar bonds between the ECZ and the 
βCD, decreasing the ring strain of the cyclodextrin, leading to the 
formation of lower energy state, more stable, inclusion complex 
resulting in improvement of solubility [41, 42]. 
There was a significant difference (p<0.05) between the solubility of 
ECZ complexes prepared by kneading method compared with co-
evaporation method. This result is similar to the results obtained by 
Al-Marzouqiet. et al. in which ECZ: βCD obtained by kneading 
method, showed drug peak disappearance in differential scanning 
colorimeter and X-ray diffraction, suggesting complex formation 
and/or sample amorphization while the product obtained by co-
evaporation method showed a small reduction in intensity of the 
drug peak, suggesting small degree of drug-cyclodextrin 
interaction[43]. Complexation by kneading seems to more suitable 
for poorly-soluble guests in contrast to co-evaporation which is 
more suitable to non-water-soluble guests [44]. 
Solubility enhancement of ECZ using kneading method was 
significantly affected by the ECZ: βCD ratio (p<0.05), increasing β-CD 
ratio to ECZ, increased the solubility, [45] as seen in fig. 1. 
The solubility diagram was both of AL type according to Higuchi and 
Connors classification, showing a linear increase of drug solubility with 
an increase in the concentration of βCD [46] both showed a type Ap 
curve which means CD is more effective at higher concentration.  
The slopes of the lines were less than one referring to formation of (1:1) 
stoichiometry, but does not exclude formation of higher ratios [45 
,47]Pedersen et al. showed that ECZ was included in βCD at a 
supersaturated ratio of 2:3 ratio, and excellent antimycotic activity [48]. 
The stability constant KS (K 1:1) of ECZ: βCD complex prepared by 
kneading method was higher than that of co-evaporation method in 
both media. The larger stability constant was observed with 
kneading method meaning itis the most suitable method for 
complexation of ECZ. Also, the Complexation Efficiency CE was 
highest for kneading method. 
  
Table 2: Stability constants Ks at (1:1) and (1:2) stoichiometry and complexation efficiency CE values of the inclusion complex of the two 
complexation methods and the initial solubility S0, in both medias 
 Complexation method  Media  Type of diagram  S0 Slope  CE K 1:1 K 1:2 * 
Kneading  Isotonic Saline Ap 0.5667±0.05 0.1914 0.236± 
0.007 
0.417 2.051 
DW Ap 0.5667±0.07 0.0817 0.088± 
0.083 
0.156 1.148 
Co-evaporation  Isotonic Saline  Ap 0.443±0.065 0.1526 0.180± 
0.091 
0.406 2.214 
DW Ap 0.443±0.008 0.0521 0.054± 
0.0089 
0.124 0.713 
*measured at βCD concentration of 0.88 x 10-3M (mean±SD, n=3) 
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Physical characters of the prepared gels 
According to the results obtained from solubility study, the 
complexes prepared by kneading method were used to prepare 
different ophthalmic gel formulas since this method enhanced the 
solubility of ECZ as mentioned previously. 
CB and SCMC combination was used to get the desired consistency, 
viscosity and appearance. Using two molar ratios of βCD and three 
different concentrations of CB were examined to achieve the desired 
release and viscosity. All the prepared gels were white soft gels. This may 
be attributed to the higher hygroscopicity of SCMC that give soft jelly 
nature in comparison to highly viscous gel prepared by CB alone [49]. 
pH 
All the prepared gels had a pH range from 6.2-6.9. 
Drug content 
ECZ content was estimated in the range of 91.5%-96.33%. The drug 
content was found to be uniform in all gel dispersion and is in good 
agreement with the theoretical drug content. 
The release study of EZC from ophthalmic gels 
The cumulative percent of ECZ release as a function of time from a 
various ophthalmic gel containing ECZ: βCD complex system 
prepared by kneading method are shown in fig. 2 and 3 and the 
corresponding release kinetics data analysis is shown in table 3. 
Three concentrations of CB where used to study their effect on the 
release of ECZ from the gel base. It was seen that increasing the 
concentration of CB from 0.5% to 1% the amount of ECZ released 
decreased for both βCD concentrations. The retardation of the 
release could be explained by increasing the overall gel viscosity 
with increasing concentration of CB polymer, [50] also the gels 
prepared using higher βCD concentration showed decrease in the 
fraction of the drug released this may be related to the capability of 
cyclodextrin cavities to retain the drug in the network, as previously 
reported for cyclodextrin-based hydrogel loaded with the 
hydrophobic hormone estradiol [51]. 
Concerning the best equation to fit the release kinetics; the n value 
of Korsmeyer Peppas equation at less than 60% release [52] of 
formulas tested, showed Super Case II transport, attributed to CB 
stress induced relaxation due to water sorption and swelling which 
takes place at the outer swollen shell of hydrophilic glassy polymer 
[53], except for the first formula in which the release was anomalous 
at lower concentration of CB and βCD so the stress induced by 
swelling is minimal and the release is due to couple effect of 
diffusion and polymer relaxation [53]. The results of Peppas–Sahlin 
equation [54] showed typical initial Fickian diffusion for formulas of 
CB 0.5 and 1%, while formulas with 0.75% CB exhibited super case 
II release in both steps, in which polymer swelling propagates 
elasticity into the vicinity of adjacent polymers [55]; thus polymer 
relaxation is the prominent step in the release of ECZ. In contrast to 
the second step of release of 0.5% and 1% CB, which showed 
anomalous and Fickian release. 
The results indicate that gel containing 0.75% CB using 0.88(10-3) M 
βCD is the more efficient formula for drug release and may be 
considered as a good candidate for ophthalmic gel dosage form since 
it has a suitable drug release profile in which about 50% of ECZ 
release is within 30 min and the best fit Super Case II transport with 
correlation coefficient r2 of 0.99. 
 
Table 3: Release kinetics data and correlation coefficient 
 βCD  0.88(10-3) M 1.76(10-3) M 
 CB % 0.5 0.75 1 0.5 0.75 1 
  t 50% 
(min)  
21.934  30.256  38.921  29.580  48.414  39.301  
Zero 
Order 
K0 2.155  2.052  1.056  1.671  1.011  1.003  
r2 0.9881  0.8839  0.9628  0.9565  0.8851  0.8555  
Korsmeyer–
Peppas 
Kkp * 3.811  0.456  0.162  0.393  0.172  0.687  
n * 0.834  1.377  1.566  1.430  1.462  1.168  
r2 * 0.9949  0.9982  0.9868  0.9581  0.9945  0.9162  










Peppas-Sahlin  K1 -25.351  0.250  -40.077  -120.035  0.120  -5058.177  
K2 20.857  0.001  24.621  83.482  0.000  5017.452  
m 0.268  1.445  0.235  0.171  1.464  0.004  
2m 0.536 2.89 0.47 0.342 2.928 0.008 
r2 0.9979  0.9916  1.0000  0.9951  0.9930  0.9390  
m Fickian  Supercase II 
transport 
Fickian Fickian Supercase II 
transport 
Fickian 
2m anomalous Supercase II 
transport 
anomalous Fickian Supercase II 
transport 
Fickian 
*Measured at less than 60% release, K0, KKP, and K1, K2 are the release constants for zero, Korsmeyer–Peppas and Peppas Sahlin equations, n,m is the 
release index for Korsmeyer–Peppas and Peppas Sahlin equations  
 
 
Fig. 2: The release of ECZ from ophthalmic gels at 0.88× !"#$βCD (mean±SD, n=3) 
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Fig. 3: The release of ECZ from ophthalmic gels at 1.76 × !"#$βCD (mean±SD, n=3 
 
Rheological properties of ECZ ophthalmic gels 
Ophthalmic ECZ gels viscosities were measured (fig. 4) and showed 
that increasing the concentration of CB resulted in an increase in 
viscosity of the gel, [56] since in gel system the viscosity depends on 
the ratio of the solid fraction which produces a structure to liquid. 
ECZ ophthalmic gels showed pseudo-plastic shear thinning with no 
thixotropy, on the rest they usually exhibit properties of the 
concentrated system due to the surface entanglement of the long 
chains between adjacent particles with each other. The profile 
showed that with increasing the shear rate the viscosity decreases. 
Applied stress will comb these entanglements out and align their 
long axes in direction of flow orientation reduce the internal 
resistance of the material and hence decrease the viscosity, with 
increasing shear rate [57, 58]. Pseudoplastic gels are preferred for 
ophthalmic application because blinking will lower the viscosity of 




Fig. 4: The viscosity of ECZ ophthalmic gels using0.88× !"#$βCD in ascending velocity and then descending (mean±SD, n=3) 
 
CONCLUSION 
The solubility of ECZ was enhanced by complexation with β 
cyclodextrin using kneading and co-evaporation, and both showed 
Ap type solubility diagram. The complex prepared by kneading 
method greatly enhanced the solubility of ECZ compared with the 
co-evaporation method. The ophthalmic gel formulated with CB and 
CMC using ECZ-βCD inclusion complex by kneading method showed 
that increasing the concentration of CB has a retardation effect on 
the in vitro release of the drug, and as the concentration of gelling 
agent increase the viscosity of the gel increase. The selected formula 
may be considered as a good candidate for ECZ ophthalmic gel 
dosage form, which showed Super case II transport release profile, 
and pseudo-plastic shear thinning behaviour. 
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